Shares of pharmaceutical company
were up about 14% for the week after the
Food and Drug Administration
expanded the approved uses of one of the company's products. The
said the transdermal drug delivery system developer could market the dime-sized estrogen patch Vivelle-Dot for the prevention of postmenopausal osteoporosis. Previously, the patch had only been approved for the treatment of menopausal symptoms. Noven said it will add a new 0.025 milligram a day strength patch to be used for the osteoporosis treatment.